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Abstract 
The misfolding and accumulation of tau protein into intracellular aggregates known as neurofibrillary 
tangles is a pathological hallmark of neurodegenerative diseases such as Alzheimer’s disease.  
However, while tau propagation is a known marker for disease progression, exactly how tau 
propagates from one cell to another and what mechanisms govern this spread are still unclear. Here, 
we report that cellular internalization of tau is regulated by quaternary structure and have developed a 
cellular assay to screen for genetic modulators of tau uptake. Using CRISPRi technology we have 
tested 3200 genes for their ability to regulate tau entry and identified enzymes in the heparan sulfate 
proteoglycan biosynthetic pathway as key regulators. We show that 6-O-sulfation is critical for tau-
heparan sulfate interactions and that this modification regulates uptake in human central nervous 
system cell lines, iPS-derived neurons, and mouse organotypic brain slice culture. Together, these 
results suggest novel strategies to halt tau transmission.   
 
The Microtubule-Associated Protein Tau (MAPT or tau) is an intrinsically disordered protein that 
under pathological conditions aggregates into filamentous inclusions known as neurofibrillary tangles 
(NFTs)1. While the composition and structure of NFTs are well characterized2,3, the in vivo process of 
aggregation is not well understood. The presence of NFTs is characteristic of a number of human 
diseases, collectively termed tauopathies. In tauopathies, such as Alzheimer’s disease (AD), NFT 
pathology advances in a predictable pattern throughout the brain affecting regions involved in 
learning and memory4. This progression of NFT pathology correlates with cognitive decline in patients 
and permits neuropathological diagnoses of patients in different stages of AD5.  
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The spread of protein aggregates during disease progression is a common theme in many 
neurodegenerative diseases, including α-synuclein in Parkinson’s disease6, Huntingtin protein in 
Huntington’s disease7, and superoxide dismutase-1 in amyotrophic lateral sclerosis8. However, the 
exact mechanisms underlying intercellular spread of these aggregates, including tau, is unclear. 
Increasing evidence suggests the transmission of tau pathology is mediated by the release, uptake, 
and trafficking of pathogenic or misfolded tau aggregates within synaptically connected neurons9,10. 
Once internalized, misfolded tau proteins act as a seed that recruits soluble endogenous tau into 
growing aggregates11. Aggregated tau is proteotoxic in model systems, suggesting that oligomeric 
and/or fibrillar tau may contribute to neurodegeneration12. However, it is unclear how the different 
quaternary architectures of tau affect internalization and if all structures have the ability to transfer 
between neurons. Further, a better understanding of the cellular processes that are necessary for 
transmission of tau aggregates could lead to the discovery of novel therapeutic strategies that would 
inhibit the spread of tau pathology and its consequences. Recent work on α-synuclein has shown that 
a cell surface receptor, lymphocyte activation gene-3 (LAG3), can bind α-synuclein and trigger its 
endocytosis into neurons13. We hypothesized that perhaps a receptor could also exist for tau.  
 
Heparan sulfate proteoglycans (HSPGs) are a diverse family of proteins modified with the linear 
sulfated glycosaminoglycan (GAG) heparan sulfate (HS). HSPGs are present in virtually all cells and 
are involved in a multitude of processes including cell attachment, migration, differentiation, and 
inflammation14. HS chains consists of a basic disaccharide building block β1-4-linked D-glucuronic 
acid (GlcA) and α1-4-linked N-acetyl-D-glucosamine (GlcNAc). During assembly, HS chains can be 
highly modified; GlcNAc residues can be N-deacetylated and N-sulfated, GlcA can be epimerized at 
C5 to L-iduronic acid (IdoA), and ester-linked sulfate groups can be installed at C2 of the GlcA/IdoA 
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and/or at C6/C3 of the GlcNAc. There is no defined template for HS modification on HSPGs. Thus, 
the availability of precursor material and abundance of biosynthetic enzymes in the cell are thought to 
dictate chain length, sulfation pattern, and epimerization15. Previous work has implicated HSPGs as a 
potential receptor for tau internalization16,17. However, this work has not examined whether specific 
HSPGs proteins or specific HS modifications on these proteins can act as determinants for tau entry, 
and therefore does not contain the molecular detail that would guide therapeutic strategies. Recent 
studies have also suggested that fragments of tau can discriminate between different sulfation 
modifications on heparin18. Within the cell there are a variety of enzymes known to be important for 
imparting this information on cellular receptors, thus we envisioned that there might be a specific 
protein or motif that would allow specification of tau entry.  
 
In this work we used central nervous system (CNS) cell lines, iPS-derived neurons, and organotypic 
slice culture to understand the guidelines for tau uptake. We find that the quaternary structure of tau 
dictates the efficiency of uptake and we used tau monomers to screen for genetic modulators of 
internalization. We found that HSPG-modifying enzymes influence tau internalization and knockdown 
of these enzymes can repress the uptake of tau. We discovered that 6-O sulfation patterns on HS 
chains are critical for tau binding, and competition or removal of these motifs on the cell surface 
reduced the internalization of tau. 
 
Results 
Internalization of tau in CNS culture is regulated by quaternary structure 
Tau protein can form multiple quaternary structures in solution, and recent evidence suggests that 
small tau oligomeric species may play a critical role in the spread of tau pathology and neurotoxicity12. 
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Furthermore, work on smaller fragments of tau have suggested that the size of tau can regulate 
seeding capacity17. Therefore, to study the rules that govern the transmission of full length tau, we 
tested the uptake capacity of various tau structures in human CNS-derived cell lines and iPS-derived 
neurons.  
 
First, we recombinantly expressed and purified the longest isoform of tau, 2N4R, and used 
established protocols to produce oligomeric and fibrillized tau species (see Methods). 
Characterization of these constructs using non-reducing SDS-PAGE analysis, revealed that tau 
monomers appear as one distinct band at ~64kDa, while tau oligomers/fibrils show additional bands 
of high molecular weight presumably for disulfide-bonded dimer, trimer, etc (Fig. 1a). TEM 
preparations of fibril samples displayed characteristic long helical filaments that could be fragmented 
upon sonication (Fig. 1a). We employed Dynamic Light Scattering (DLS) analysis to further 
characterize our tau constructs19. Analysis of our different tau species (Fig. 1b) showed, as expected, 
that monomeric tau was monodispersed and small in average size (5.7 ± 0.9nm), whereas oligomers, 
sonicated fibrils and fibrils were larger and more dispersed (19 ± 3nm, 33 ± 11nm, and 80 ± 8nm 
respectively).  
 
To test the efficacy of these tau species towards internalization by cells, we labeled each protein 
preparation with an Alexa Fluor-488 (AF488) probe and then added various concentrations of protein 
to the cell media of H4 neuroglioma cells. After one hour, cells were washed, lifted from the plate and 
analyzed for fluorescence using flow cytometry. To control for non-specific binding to the membrane, 
identical experiments were performed at 4°C (a non-permissive temperature for endocytosis), and 
any fluorescence observed was subtracted from our results. Monomeric, oligomeric and sonicated 
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fibrils were efficiently internalized, while fibril samples were not (Fig. 1c). Tau uptake was a time-
dependent process, with uptake observed in as little as 10 minutes (Supplementary Fig. 1a). This 
assay for tau uptake was robust for other human CNS cell lines, including SHSY-5Y neuroblastoma, 
and ReN VM neural progenitors (Supplementary Fig. 1b,c). Further, human iPS-derived neurons also 
showed a preference for smaller structures of tau, with fibrillized tau showing nearly no uptake (Fig. 
1d). Taken together, these results suggest that cellular uptake of tau is regulated by size and that 
large species of tau are inefficiently internalized across multiple cell types. 
 
Functional genomics to find modulators of tau uptake 
With a robust and high-throughput assay for tau uptake in hand, we used this platform to screen for 
genetic modulators that could either increase or decrease tau internalization. To do this, we 
developed an H4 CRISPRi cell line that stably expresses a catalytically inactive Cas9 fusion protein 
(dCas9-KRAB). CRISPRi represses transcription of genes with high specificity using single guide 
RNAs (sgRNAs) that guide the dCas9-KRAB protein to the transcription start site (TSS) of the 
targeted gene20. As a proof of concept, we screened a next-generation CRISPRi library of sgRNAs 
that targeted 3200 different genes with five different sgRNAs per gene, and contained hundreds of 
non-targeting negative-control sgRNAs21. H4 CRISPRi cells transduced with sgRNAs were then 
incubated with 25nM AF488 labeled 2N4R monomer (2N4R-488) for 1hr and sorted based on AF488 
fluorescence. The cell populations with the top and bottom thirds of AF488 fluorescence, representing 
higher than average and lower than average tau uptake, respectively, were recovered, genomic DNA 
was isolated and the locus encoding the sgRNA was PCR-amplified and frequencies of each sgRNA 
in the two populations were determined by next-generation sequencing (Fig. 2a). To detect hit genes, 
peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/167874doi: bioRxiv preprint first posted online Jul. 24, 2017; 
 7 
we applied our previously developed quantitative framework for pooled genetic screens22,23 as 
described in the Methods.  
  
We selected sixteen genes for individual validation studies, including genes with particularly strong 
phenotypes in the primary screen, as well as genes in pathways previously implicated in tau uptake. 
Fifteen of the sixteen follow-up hits were found to repress expression of their target gene (i.e. 
knockdown) as determined by qPCR (Supplementary Fig. 2a). Fourteen of the fifteen gene 
knockdowns also reproduced their screen phenotype i.e. either increased or decreased tau uptake as 
compared to a non-targeting sgRNA control (Fig. 2b and Supplementary Fig. 2b).  
 
Interestingly, we found that some of the strongest phenotypes in our screen were attributed to genes 
that are known cell cycle regulators (Supplementary Fig. 2c). The selective knockdown of genes such 
as TP53, led to a decrease in G1 length and thus an overall increase in cell proliferation 
(Supplementary Fig. 2d). Endocytosis is known to increase during G1 phase24; therefore, it seemed 
logical that cell cycle regulators that can shorten the G1 phase could reduce the amount of tau uptake 
and vice versa. In line with these observations a small molecule inhibitor of CDK4/6 that causes a 
stall in G1 phase (PD0332991) was sufficient to almost double the amount of tau taken up in H4 cells 
(Supplementary Fig. 2e). Further work will be needed to dissect if and how these genes might 
influence post-mitotic neurons. 
 
Hits that were of particular interest included genes involved in heparan sulfate proteoglycan (HSPG) 
biosynthesis (EXT2 and HS6ST1) as well as DNM2, a GTPase involved in endocytosis. These single 
gene knockdowns repressed uptake of tau monomer by over 50% (Fig. 2b) and also reduced the 
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uptake of tau oligomers (Fig. 2c). Further, these gene knockdowns were sufficient to reduce the 
uptake of tau in iPS-derived neurons (Fig. 2d). Treatment of cells with an inhibitor for DNM2, 
Dynasore, was also able to reduce uptake of tau (Supplementary Fig. 2f).  
 
Tau binds to heparin derivatives and shows specificity for 6-O-sulfated heparins 
Based on our pilot screen results, we were particularly interested in the enzymes involved in HSPG 
biosynthesis. Previous reports had indicated that internalization of tau could be regulated by 
HSPGs16, but our identification of HS6ST1, an enzyme that is responsible for 6-O sulfation of HSPGs, 
supports a hypothesis that specific motifs on HSPGs might be important for tau uptake.  
 
HSPGs are decorated with HS chains that consist of a repeating GlcA-GlcNAc building block. During 
assembly, HS chains can be highly modified and, importantly for their function, they can be sulfated 
at multiple sites within the disaccharide (Fig. 3a). To ascertain whether specific sulfation motifs were 
important for tau binding, we employed a heparin ELISA assay. In this assay, biotin-labeled heparin 
derivatives (Fig. 3b) were immobilized on streptavidin-coated plates, purified tau protein was 
incubated with the plate at increasing concentrations, and antibodies were used to detect tau binding. 
Tau bound heparin with an affinity of 4.6 ± 0.6nM, consistent with previous reports25. Over sulfated 
heparin (>3 sulfates per disaccharide) bound tau even tighter (2.2 ± 0.5nM), while fully-desulfated 
heparin showed a drastically reduced binding (>1μM) (Fig. 3c). Removal of N-sulfates or 2-O sulfates 
had little effect on tau binding (15.0 ± 5nM and 7.4 ± 1.0nM, respectively), while removal of all O-
sulfates and, in particular 6-O sulfates, led to a significant decrease in tau binding (>1μM in each 
case; Fig. 3c,d). The relative binding of 6-O desulfated heparin in the presence of 10nM tau was 6.9% 
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that of heparin, consistent with our hypothesis that tau interacts with the 6-O sulfation motif on HS 
chains, and that HS is important for tau internalization. 
 
Cellular internalization of tau is effected by the presence of 6-O-sulfation 
To confirm that 6-O sulfation was indeed a determinant of tau uptake, we developed a cellular 
competition experiment to monitor tau internalization. In this experiment, we added heparin or heparin 
derivatives free into the cell media immediately prior to addition of 2N4R-488. We found that 
internalization of tau can be efficiently competed by the presence of heparin or HS in the media (Fig. 
4a). Likewise, addition of 2-O desulfated heparin was able to reduce uptake, whereas 6-O desulfated 
heparin or chondroitin sulfate (negative control) were significantly less effective at reducing uptake 
(Fig. 4a). These results were consistent when tested in iPS-derived neurons (Fig. 4b), demonstrating 
that the 6-O sulfation motif is indeed a critical determinant for cellular tau entry.  
 
To test if HS 6-O sulfation would also prevent internalization of tau in an ex vivo system, we 
generated organotypic brain slices from adult mice using established methods26. These slices 
showed normal electrophysiology, suggesting good vitality (Supplementary Fig. 3a). Their ability to 
uptake tau was tested by incubating the cultures with 2N4R-488 for 30min at 37°C or, as a control, 
4°C. The cultures were washed, stained with Hoechst dye to label nuclei, and mounted on coverslips 
to image. Incubation at 37°C showed uptake of tau in the slice cultures, whereas very little 
fluorescence was observed in the 4°C control cultures (Fig. 4c and Supplementary Fig. 3b). 
Consistent with our previous results, incubation with heparin, heparan sulfate, or 2-O desulfated 
heparin reduced uptake of tau as quantified by the median 488 fluorescence intensity (Fig. 4d). 
Chondroitin sulfate and 6-O desulfated heparin incubation did not reduce the median fluorescence, 
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verifying that 6-O sulfation is also important for tau internalization ex vivo (Fig. 4d and Supplementary 
Fig. 3b). Quantification of median Hoechst fluorescence across all the images showed that similar cell 
numbers were analyzed for each condition (Supplementary Fig. 3c).  
 
Finally, in order to test if direct removal of 6-O sulfates from the cell surface could reduce uptake of 
tau in cell culture, we overexpressed two different extracellular endosulfatases (Sulf1 & Sulf2) that 
selectively cleave 6-O sulfates on GlcNAc27. Overexpression of these enzymes in H4 cells, showed a 
dramatic decrease in tau uptake with Sulf1 reducing uptake to 17 ± 9%, and Sulf2 reducing uptake to 
36 ± 15% (Fig. 4e). Overexpression of the constructs was confirmed with immunocytochemistry (Fig. 
4f).  
 
Discussion 
In recent years, a growing body of literature has reinforced the hypothesis that prion-like cell-to-cell 
propagation of protein aggregates underlies disease progression of numerous neurodegenerative 
disorders28. For some of these protein aggregates (PrP, α-synuclein), specific pathways and protein 
conformers that are key for transmission have been delineated quite fully13,29. However for other 
proteins, such as tau, many details regarding its transmissibility are still unclear. It has been shown in 
various cellular and animal models that exogenously added tau aggregates can induce tau 
pathology9,30; however, the disparity between the experimental systems and the tau species used in 
each study makes it hard to draw a unifying theme. Tau is a complex protein that has several 
isoforms, posttranslational modifications, and the ability to form multiple quaternary structures31. 
Therefore, we have focused our research on the development of a cellular assay that can robustly 
detect internalization across various tau constructs and CNS cell systems.  
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The data presented here demonstrate that full-length human tau (2N4R) can be efficiently internalized 
across multiple relevant cell systems and that this uptake is dependent on the overall size of the tau 
species. This is a critical point, since it is still debated exactly how tau induces neurotoxicity. One 
hypothesis suggests that tau oligomers are the toxic species and that the formation of tau fibrils inside 
neurons (NFTs) is a protective mechanism. This is supported by neuropathological studies in AD 
patients where neuronal loss and cognitive deficits precede NFT formation32. Our data are consistent 
with this hypothesis, as tau fibrils were unable to be internalized, and thus would be unable to “seed” 
misfolding inside the cell. This does not, however, discount the potential for synaptic transmission or 
exosome transfer of fibrils between neurons33. But, as tau oligomers and monomers have been found 
elevated in the CSF of AD patients34,35, it seems likely our assay recapitulates at least one in vivo 
scenario.  
 
Using CRISPRi technology, we identified multiple genetic factors that can influence the uptake of tau 
in cell culture. The identification of HSPGs as regulators of tau internalization is not an entirely new 
concept. Indeed, it has been known for years that tau can bind heparin, and that this molecule can be 
used as an in vitro inducer of aggregation36. However, our work has shown that binding of tau to HS 
is directly related to the sulfation pattern, and specifically on the presence of 6-O sulfates on the 
glucosamine subunit. Further work will be needed to understand if there are specific HS chain lengths 
or regions on tau that are important for this interaction.  
 
This work is an important step forward in the characterization of HS-tau interactions. With these new 
insights we can begin to envision ways to design small molecules that mimic the HS structures that 
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interact with tau to block its aggregation and neutralize its toxicity. It is plausible to expect that novel 
treatments that target the HS-tau interaction may contribute to AD treatment and could improve the 
effects of other treatments.  
 
Methods 
Chemicals 
Heparin, chondroitin sulfate, heparan sulfate, and desulfated heparins (Neoparin & Galen Labs 
Supplies). Dynasore hydrate (Sigma). Hoechst (Thermo Scientific). 
 
Protein Purification, Labeling and Fibrillization 
Full length tau protein (2N4R, 1-441aa) was purified with slight modification to previously published 
protocols37. Briefly, 2N4R tau in the pRK172 plasmid was expressed in E. coli BL21 (DE3). Cell 
pellets were harvested and resuspended in cell lysis buffer (50mM MES pH 6.5, 5mM DTT, 1mM 
PMSF, 1mM EGTA) + cOmplete protease inhibitor tablets (Roche). Lysate was sonicated, boiled for 
10min, and then centrifuged at 50,000xg for 30min at 4°C. The supernatant was then precipitated 
with ammonium sulfate (20% w/v) and centrifuged at 20,000xg for 30min at 4°C. The pellet was 
resuspended into 4mL of MonoS Buffer A (50mM MES pH 6.5, 50mM NaCl, 2mM DTT, 1mM PMSF, 
1mM EGTA) and dialyzed overnight against the same buffer. The protein was loaded onto a MonoS 
column (GE Healthcare) and eluted with a linear gradient of NaCl using MonoS Buffer B (Buffer A + 
1M NaCl). Fractions containing 2N4R tau were pooled, concentrated, and dialyzed overnight into 
PBS pH 7.4. Protein concentration was determined using a BCA assay (Thermo Scientific).  
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Protein was labeled with Alexa Fluor® 488 or 647 5-SDP ester (Life Technologies) according to the 
suppliers instructions. After labeling, 100mM glycine was added to quench the reaction and the 
proteins were subjected to Zeba desalting columns (Thermo Scientific) to remove any unreacted 
label. Average label incorporation was between 1 and 1.5 moles/mole of protein, as determined by 
measuring fluorescence and protein concentration (Amax x MW of protein / [protein] x εdye). To prepare 
tau fibrils and oligomers, 10uM protein, in PBS 1mM DTT pH 7.4, was mixed with heparin 
(0.05mg/ml) and incubated with shaking at 37°C. The formation of oligomers was observed after 4h of 
shaking, whereas fibril formation was formed after 5 days30. To make sonicated fibril samples, 
fibrillized protein was sonicated using a MiSonix Sonicator 4000 (QSonica, LLC) at 50% amplitude for 
60 1s pulses.   
 
Transmission Electron Microscopy 
Tau fibrils and sonicated fibrils (1μM) were absorbed on 200-mesh formvar-coated copper grids, 
washed, and stained with a 2% uranyl acetate solution. Grids were then imaged with a JEOL JEM-
1230 (JEOL USA, Inc) at the indicated magnifications.  
 
Dynamic Light Scattering 
Protein solutions (1μM) were filtered (0.45μm) and analyzed using a Zetasizer Nano ZS (Malvern). 
The time-dependent autocorrelation function of the photocurrent was acquired every 10s, with 15-20 
acquisitions for each run and with at least three repetitions. The error bars displayed on the DLS 
graphs were obtained by the standard deviation (SD) between replicates.  
 
Cell Culture, Transfections and Treatments 
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H4 cells were cultured in DMEM supplemented with 10% FBS, 100μg/ml penicillin/streptomycin. 
SHSY-5Y cells were cultured in DMEM/F12 supplemented with 10% FBS, 100μg/ml 
penicillin/streptomycin. ReN-VM cells were cultured on Matrigel (Corning) coated plates in 
DMEM/F12 supplemented with 2μg/ml heparin (STEMCELL Technologies), 2% B27 (Life 
Technologies, 100μg/ml penicillin/streptomycin, 20μg/ml bFGF (Stemgent), 20μg/ml EGF (Sigma). 
Cultures were maintained in a humidified atmosphere of 5% CO2 at 37°C. Transfection of H4 cells 
with Sulf1 (Addgene #13003) or Sulf2 (Addgene #13004) were performed with Lipofectamine 3000 
(Invitrogen) according to the manufacturers instructions and cells were assayed 48h later. 
Overexpression was confirmed with immunocytochemistry using the his tag epitope (see 
supplemental methods). For competition experiments, heparin (and various derivatives) was added to 
the media just prior to tau addition at the indicated concentrations.  
 
iPS Culturing and Differentiation 
CRISPRi iPSc with an inducible TRE3G-dCas9KRAB-T2A-mCherry were maintained in 6-well 
Matrigel (Corning) coated plates with mTeSR1 media (STEMCELL Technologies) and split with 
ReLeSR (STEMCELL Technologies) at a 1:20 ratio every 4-5 days. For differentiation, CRISPRi cells 
were split with Accutase and virally infected twice with a NeuroD1-IRES-eGFP-Puro (Addgene 
#45567) according to previously published methods38. Doxycyclin was added to induce expression of 
NeuroD1, and the following day cells were selected with puromycin (5μg/ml). After selection, cells 
were lifted with Accutase treatment and replated 1:12 in PEI coated 24-well plates. Three days later, 
media was changed to Brain Phys Neuronal Medium (STEMCELL Technologies) with doxycycline 
and AraC to remove any remaining dividing cells. At day 8, cells were infected with specific sgRNA 
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constructs. iPS neurons were assayed between days 14-18 of maturity as described below. 
Immunocytochemistry was used to confirm neuronal properties (Supplementary Fig. 1d). 
 
Flow Cytometry 
H4 cells were plated at 50,000 cells per well in a 24-well plate. The next day media was replaced, and 
cells were treated with varying concentrations of AF488-labeled tau protein for 1hr (unless indicated 
otherwise) at 37°C. Cells were then washed twice with PBS and trypsinized to lift cells from the plate. 
Identical control experiments were performed at 4°C to confirm that tau protein was internalized and 
not just adhering to the cell membrane. Lifted cells were analyzed using an Accuri-C6 Flow 
Cytometer and propidium iodide was used to exclude dead cells from the analysis.  
 
CRISPRi Screen 
We generated a stable CRISPRi-enabled H4 neuroglioma cell line by transducing H4 cells with the 
lentiviral plasmid pHR-SFFV-dCas9-BFP-KRAB39 and selecting a polyclonal population of BFP-
expressing cells by FACS. These cells were transduced with a next-generation CRISPRi sgRNA 
library (sublibrary “Cancer and Apoptosis”)21, and transduced cells were selected using puromycin 
(1μg/mL). Media was replaced with fresh DMEM containing AF488-labeled Tau monomers at a final 
concentration of 25nM for 1 hr at 37°C. Cells were washed twice, trypsinized, and resuspended in 
FACS buffer (PBS with 0.5% FBS). A BD-FACAria II, was used to sort live cells into two populations 
based on the top and bottom thirds of AF488 fluorescence; approximately 15 million and 17 million 
cells were recovered from the high- and low-fluorescence populations, respectively. The resulting 
DNA was isolated, the cassette encoding the sgRNA was amplified by PCR, and relative sgRNA 
abundance was determined by next-generation sequencing as previously described20,23. We analyzed 
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the resulting data using our previously developed quantitative framework for pooled genetic 
screens22,23. Statistical significance for each targeted transcription start site was calculated using the 
Mann-Whitney U test to compare the phenotypes of the 5 sgRNAs targeting the transcription start site 
to the phenotype distribution of the 280 non-targeting sgRNAs in the library. 
 
ELISA 
Heparin/heparin derivatives were biotinylated using EZ-link Sulfo-NHS-LC-Biotin (Thermo) and 
immobilized on streptavidin-coated plates, followed by a 2 hr incubation with 2N4R tau protein 
containing a C-terminal myc tag (10-fold dilution series). Bound tau was detected using an anti-myc 
HRP-conjugated antibody  (Bethyl, A190-105P), visualized using TMB substrate (R&D Systems), and 
quantified by UV-Vis. Absorbance for each plate was measured at 450 and 550nm. The 550nm 
measurement is a correction for plate imperfections and was subtracted from the 450nm values. Data 
were normalized to heparin controls and fit with a Hill binding mathematical model where appropriate 
using the equation Y=Bmax*X^H/(Kd^H + X^H), where H is the Hill slope (variable), X is the 
concentration of tau, and Bmax is the binding maximum. 
 
Organotypic Slice Culture & EPSP measurements 
Slice cultures were prepared as previously described26. Hippocampal excitatory postsynaptic 
potentials (EPSPs) were measured using a multi-electrode array (MEA). Stimulus current was 
injected into a region of the hippocampal slice by an MEA electrode, with the magnitude of stimulus 
current ranging from 20-80 μA. EPSPs were then measured by recording an electrode in a different 
region of the hippocampal slice. Smaller stimulus currents excite fewer cells, and thus the measured 
EPSPs have smaller magnitudes. 
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qPCR 
Purelink RNA Extraction Kit (Invitrogen) was used to isolate RNA from samples. RNA (1μg) was then 
converted to cDNA using SuperScript Reverse Transcriptase III (Invitrogen) according to the 
supplier’s instructions. Real-time quantitative PCR was performed using Power SYBR Green PCR 
Master Mix (Applied Biosystems) according to QuantStudioTM 12K Flex Real-Time PCR System 
protocol. GAPDH mRNA level was used to normalize samples.  
 
Immunocytochemistry 
Cells were fixed with 4% paraformaldehyde for 15min at RT followed by three washes with PBS. Cells 
were permeabilized with 0.25% Triton X-100 in PBS, and blocked for 1hr in blocking buffer at RT (1% 
BSA, 300mM Glycine, 0.1% Gelatin, 4% Donkey Serum in TBST). After blocking, cells were 
incubated with primary antibodies diluted in blocking buffer overnight at 4°C. The day after cells were 
washed three times (5 min each) with 0.05% Tween-20 in PBS. The following primary antibodies 
were used: Tau-46 (Invitrogen, 36400, 1:1000), MAP2 (Millipore, AB5622, 1:1000), and anti-his 
(Thermo Scientific, MA1-21315, 1:1000). Secondary antibodies (Life Technologies, A21422, A21206, 
1:1000) were incubated for 1hr at RT, washed three times with 0.05% Tween-20 in PBS and imaged 
with an Olympus IX71 Microscope 
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Figures and Legends 
Figure 1. Tau uptake is regulated by quaternary structure. (a) 2N4R monomer, oligomer, and 
fibrillized proteins show distinct banding patterns on a non-reducing SDS-PAGE gel. 2N4R Fibrils 
before (top) and after (bottom) sonication as visualized by negative-stain EM. Bar represents 500nm 
(b) DLS of 2N4R monomer, oligomer, fibril, and sonicated fibril species. Experiments were performed 
75
100
150
250
50
37
MW (kDa)
Monomer Oligomer Fibril
2N4R2N4R2N4R
1 10 100 1000
0
5
10
15
20
25
Size (d, nm)
Vo
lu
m
e
 
%
2N4R Monomer
2N4R Oligomer
2N4R Sonicated Fibril
2N4R Fibril
0 50 100 150 200
0
50
100
Protein (nM)
%
 
po
si
tiv
e
 
ce
lls
Monomer
Oligomer
Sonicated Fibril
Fibril
a b
c d
Monomer
Oligomer
Sonicated Fibril
Fibril
0 50 100 150 200
0
20
40
60
80
Protein (nM)
%
 
po
si
tiv
e
 
ce
lls
peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/167874doi: bioRxiv preprint first posted online Jul. 24, 2017; 
 22
in triplicate and the error shown is SD. (c) Uptake of 2N4R quaternary structures in H4 cells. (d) 
Uptake of 2N4R quaternary structures in iPS-derived neurons. For all uptake experiments, three 
independent experiments were performed in duplicate, identical control experiments were performed 
at 4°C and subtracted from 37°C data to generate final curves shown, and the error shown is SEM. 
 
 
 
 
Figure 2. CRISPRi screen for tau uptake modulators. (a) Screening strategy using H4 CRISPRi 
cells, see text for details. (b) Reconfirmation of selected hits in H4i cells with 2N4R monomer (50nM), 
normalized to a WT (no sgRNA) control. (c) Uptake of 2N4R oligomers (50nM) in H4i cells with 
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selected gene knockdowns, normalized to a WT (no sgRNA) control. (d) Uptake of 2N4R monomer in 
iPS-derived neurons with selected gene knockdowns, normalized to a WT (no sgRNA) control. All 
uptake experiments were performed in duplicate over three independent experiments with the data 
combined. Lines on the graphs represent WT mean +/- 3 standard deviations, error bars represent 
SEM, a one-way ANOVA analysis with Dunnett’s method was used to determine significance 
between the gene knockdown and the non-targeting sgRNA *=p-value ≤0.05, **=p-value ≤0.01, ***=p-
value ≤0.001. 
 
Figure 3. Binding of tau to heparin derivatives. (a) HS chains consist of GlcA/IdoA-GlcNAc 
disaccharide units that can be modified at positions indicated in red and blue. (b) List of 
heparin/heparin derivatives that were used and description of their sulfation modifications. (c) Binding 
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of 2N4R to various heparin derivatives by ELISA with data fit to a Hill binding model (line) where 
appropriate. (d) Normalized relative binding of 2N4R (10nM) to various heparin derivatives. Three 
independent experiments were performed, data were normalized to heparin controls, and the error 
shown is SD.  
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Figure 4. 6-O sulfation regulates tau uptake in CNS culture. (a) Internalization of 2N4R-488 into 
H4 cells is strongly inhibited by incubation with heparin, heparan sulfate, and 2-O desulfated heparin 
as compared to 6-O desulfated heparin or chondroitin sulfate. (b) Internalization of 2N4R-488 into 
iPS-derived neurons is inhibited by incubation with heparin, heparan sulfate, and 2-O desulfated 
heparin as compared to 6-O desulfated heparin or chondroitin sulfate. All uptake experiments were 
performed in duplicate over three independent experiments with the data combined. Lines on the 
graphs represent WT mean +/- 3 standard deviations, error bars represent SEM, and a one-way 
ANOVA analysis with Dunnett’s method was used to determine significance compared to the negative 
control *=p-value ≤0.05, **=p-value ≤0.01, ***=p-value ≤0.001, ns = not significant. (c) Internalization 
of 2N4R-488 into mouse organotypic slice culture is strongly inhibited by incubation with 2-O 
desulfated heparin, but not 6-O desulfated heparin. Hoechst stain is used to label nuclei. (d) 
Quantification of the median 488 fluorescence intensity for tau uptake in mouse slice culture. Two 
independent experiments were performed with multiple images (>5) from each condition. Error bars 
represent SEM. (e) Uptake of 2N4R-488 tau is reduced when Sulf1 or Sulf2 is overexpressed in H4 
cells as compared to WT or mock transfected cells. Uptake experiments were performed in duplicate 
over three independent experiments with the data normalized to WT and combined. Error bars 
represent SEM. (f) ICC confirms that Sulf1 and Sulf2 are overexpressed (red) in H4 cells. Hoechst 
stain is used to label nuclei. 
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